| |||||||
| |||||||
| |||||||
1 | HOUSE RESOLUTION
| ||||||
2 | WHEREAS, The Illinois Department of Public Health's May | ||||||
3 | 2022 report recorded 3,013 fatalities that occurred in 2021 | ||||||
4 | due to opioid overdoses; and
| ||||||
5 | WHEREAS, The 3,013 Illinois opioid overdose deaths | ||||||
6 | represent a 2.3% increase from 2020 and a 35.8% spike from | ||||||
7 | 2019; and
| ||||||
8 | WHEREAS, In 2021, toxicology testing found that 2,672 | ||||||
9 | (89%) of the opioid fatalities involved a synthetic opioid, | ||||||
10 | such as fentanyl; and
| ||||||
11 | WHEREAS, A 4 mg naloxone hydrochloride nasal spray has | ||||||
12 | been the principal tool used by bystanders and emergency | ||||||
13 | medical services (EMS) to revive an individual from an | ||||||
14 | overdose episode; and | ||||||
15 | WHEREAS, A study, published in the Harm Reduction Journal | ||||||
16 | in May 2022, surveyed 125 adult U.S. residents who had been | ||||||
17 | administered 4 mg Naloxone nasal spray during an opioid | ||||||
18 | overdose and found that 78% used 2 or more doses and 30% used 3 | ||||||
19 | or more doses of Naloxone; and | ||||||
20 | WHEREAS, A 2021 Johns Hopkins Bloomberg School of Public |
| |||||||
| |||||||
1 | Health study published in the Harm Reduction Journal reported | ||||||
2 | on a survey of 171 people who use opioids in suburban Maryland; | ||||||
3 | sixty-one (35.7%) of these people who use opioids had received | ||||||
4 | take-home naloxone over a six month period: 57% of naloxone | ||||||
5 | recipients used it to reverse an overdose; 79% of overdose | ||||||
6 | reversals reported needing more than 2 doses; and | ||||||
7 | WHEREAS, Published by the National Library of Medicine, a | ||||||
8 | study of the National Emergency Medical Services Information | ||||||
9 | System Database of more than 10,000 EMS agencies across 47 | ||||||
10 | states with 946,000 calls giving Naloxone shows that use of | ||||||
11 | Naloxone multi-dosing by EMS increased 54% over five-years, | ||||||
12 | from 18.4% to 28.4% in 2020; and | ||||||
13 | WHEREAS, On April 30, 2021, the U.S. Food and Drug | ||||||
14 | Administration approved a higher 8 milligram dose of naloxone | ||||||
15 | hydrochloride nasal spray product to treat opioid overdose; | ||||||
16 | and | ||||||
17 | WHEREAS, Thirty-four U.S. States have open access to the 8 | ||||||
18 | mg naloxone nasal spray on their Naloxone Standing Orders, | ||||||
19 | including Ohio, Kentucky, Iowa, Pennsylvania, Massachusetts, | ||||||
20 | New Jersey, Virginia, Alabama, Florida, Tennessee, Colorado, | ||||||
21 | Alaska, New Hampshire, Illinois, Arizona, Kansas, California, | ||||||
22 | Texas, Georgia, South Carolina, North Carolina, West Virginia, | ||||||
23 | Michigan, Connecticut, Oklahoma, Minnesota, Maine, Louisiana, |
| |||||||
| |||||||
1 | Nevada, Idaho, Oregon, Nebraska, and Vermont; and | ||||||
2 | WHEREAS, Thirteen state government agencies have purchased | ||||||
3 | the 8 mg Naloxone nasal spray, including Alabama, Alaska, | ||||||
4 | Colorado, Florida, Idaho, Iowa, Kentucky, New Hampshire, Ohio, | ||||||
5 | Pennsylvania, Tennessee, Wisconsin, and West Virginia; and | ||||||
6 | WHEREAS, The U.S. Veterans Administration added the 8 mg | ||||||
7 | naloxone nasal spray to the National Formulary in November | ||||||
8 | 2021; and | ||||||
9 | WHEREAS, 70% of the number of lives covered by commercial | ||||||
10 | insurance in the U.S. can access the 8 mg naloxone nasal spray; | ||||||
11 | and | ||||||
12 | WHEREAS, 90% of the number of lives covered by Medicaid | ||||||
13 | insurance in the U.S. (40 states) can access the 8 mg naloxone | ||||||
14 | nasal spray, including Illinois; and
| ||||||
15 | WHEREAS, The current cost of the 4 mg naloxone nasal spray | ||||||
16 | is $5.93 per milligram and the 8 mg version is $3.75 mg, or | ||||||
17 | 36.7 percent less; and
| ||||||
18 | WHEREAS, Being good stewards of taxpayer money is a | ||||||
19 | priority for the Illinois General Assembly; therefore, be it
|
| |||||||
| |||||||
1 | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE | ||||||
2 | HUNDRED SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that | ||||||
3 | we strongly urge the Illinois Department of Human Services to | ||||||
4 | review the value of expanding its naloxone tool kit to include | ||||||
5 | all U.S. Food and Drug Administration-approved versions of | ||||||
6 | naloxone to fight the Illinois opioid epidemic; and be it | ||||||
7 | further
| ||||||
8 | RESOLVED, That suitable copies of this resolution be | ||||||
9 | delivered to the Governor of Illinois, the Governor's Chief | ||||||
10 | Behavioral Health Officer, the Secretary of the Department of | ||||||
11 | Human Services, and the Director of the Division of Substance | ||||||
12 | Use, Prevention and Recovery.
|